Latest Content

In the first ever episode of "On Your Mind With Erin Crown," explore how tribalism hurts the field of psychiatry and ultimately patient outcomes.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.

Check out the pipeline updates from June!

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.

David Dunner, MD, FACPsych, reveals insights into rapid cycling roots, bipolar II, and weighing lithium as an often overlooked treatment option.

Transgender psychiatrists of color share APA first-panel insights on identity, allyship, and gender-affirming care—urging intersectional, culturally engaged mental health practice.

Estrogen shapes schizophrenia in women: onset peaks, dosing shifts, and relapse risk from periods to pregnancy, postpartum, and menopause.

Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.

Phase 2 IRIS finds ML-004 misses social communication goals in autism, but notably reduces irritability in teens.

FDA issues CRL for cytisinicline, citing manufacturing issues.

Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.